Recent studies into retatruptide peptide reveal promising outlook for addressing weight and type 2 diabetes. The peptide, a dual agonist of GLP-1 receptor and GIP, seems to present greater weight reduction and glycemic control versus existing therapies. Additional clinical trials are needed to fully evaluate its well-being record and extended effic